Send us Feedback

Abraxis BioScience (ABII)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW

ABII » Topics » Nab Pipeline

This excerpt taken from the ABII 8-K filed Apr 1, 2008.

Nab™ Pipeline

Abraxis intends to leverage its nab™ tumor targeting technology and internal clinical development and regulatory expertise to develop numerous drug candidates for the treatment of cancer and other critical illnesses. The drug candidates which have achieved Phase I or IND status include ABI-008 (nab™-docetaxel), ABI-009 (nab™-rapamycin), ABI-010 (nab™-17AAG) and Coroxane™.

 

4

Abraxis BioScience, Inc.

2007 Fourth Quarter/Full Year Financial Results

 

ABI-008 (nab™-docetaxel): ABI-008 is a solvent-free nanometer-sized form of docetaxel, a widely used taxane marketed as Taxotere®. An investigational new drug application, or IND, was filed for ABI-008 in the fourth quarter of 2006. In the second quarter of 2007, the company initiated a Phase I/II trial with ABI-008, the second drug based on its nab™ technology to enter clinical development. The Phase I/II trial will evaluate the safety, tolerability and anti-tumor activity of nab™-docetaxel given every three weeks for the treatment of hormone refractory prostate cancer. The company anticipates that pivotal trials for MBC, NSCLC and prostate cancer will be initiated in 2009.

ABI-009 (nab™-rapamycin): ABI-009 is an albumin-bound nanoparticle of rapamycin able to be administered intravenously. An IND for ABI-009 was filed in December 2006. Clinical studies began in the fourth quarter of 2007.

ABI-010 (nab™-17AAG): ABI-010 is a solvent-free albumin-bound form of 17AAG. The company has submitted an IND for nab™-17AAG in the first quarter of 2008.

Coroxane™: Coroxane™ is currently in Phase II clinical studies for coronary restenosis as well as peripheral artery (superficial femoral artery) restenosis. Administered with bare metal stents, Coroxane™ may address the issue of incomplete re-endothelialization and acute thrombosis associated with drug-eluting stents. Coroxane™ administered following balloon angioplasty in the superficial femoral artery may help reduce the incidence of restenosis in these patients. The company currently intends to seek a strategic partner for the further development and marketing of Coraxane™.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki